Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951002 | 0.84 | CHRNA7 (0.37) | CHRNA7 | |
| SCHEMBL9686431 | 0.76 | ALDH1A1 (0.33) | LMNA | |
| SCHEMBL29740320 | 0.74 | — | — | |
| SCHEMBL154932 | 0.74 | — | — | |
| SCHEMBL2738305 | 0.72 | APLNR (0.38) | CHRNA7 | |
| Ammonia Solution, Strong SCHEMBL22960694 | 0.71 | — | — | |
| SCHEMBL22960697 | 0.71 | — | — | |
| SCHEMBL22960695 | 0.71 | — | — | |
| SCHEMBL21928710 | 0.70 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL933581 | 0.70 | NOS3 (0.40) | CHRNA7HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332155-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE ONCOLOGY LTD (IN) | 2025-10-30 | — | — | US | disclosed |
| US-12377088-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | AURIGENE ONCOLOGY LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| WO-2023104714-A1 | PESTICIDALLY ACTIVE PYRIDAZINONE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023072849-A1 | PESTICIDALLY ACTIVE PYRIDAZINONE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| US-20220125780-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-04-28 | — | — | US | disclosed |
| US-20220125780-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11229636-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-01-25 | — | — | US | disclosed |
| US-11229636-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-01-25 | — | — | US | disclosed |
| US-20180200247-A1 | Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-07-19 | — | — | US | disclosed |
| US-20180200247-A1 | Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-07-19 | — | — | US | disclosed |
| EP-3294713-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | Aurigene Discovery Technologies Limited (IN) | 2018-03-21 | — | — | EP | disclosed |
| US-9845332-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-19 | — | — | US | disclosed |
| WO-2016185342-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016185342-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2012082853-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377088-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | RORC, RORA, RORB | CHRNA7 493/4885GABRA1 146/4885GABRB2 240/4885 |
| US-20250332155-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | RORC, RORA, RORB | CHRNA7 493/4885GABRA1 146/4885GABRB2 240/4885 |
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | CHRNA7 39/4885GABRA1 45/4885GABRB2 29/4885 |
| US-11229636-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | RORC, RORA, RORB | CHRNA7 493/4885GABRA1 146/4885GABRB2 240/4885 |
| US-20180200247-A1 | Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators | RORC, RORA, RORB | CHRNA7 493/4885GABRA1 146/4885GABRB2 240/4885 |
| US-20220402948-A1 | EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR | EGFR, ERBB2, ERBB3 | CHRNA7 4816/4885GABRA1 2558/4885GABRB2 3547/4885 |
| US-20220125780-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | RORC, RORA, RORB | CHRNA7 493/4885GABRA1 146/4885GABRB2 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.